![Flatiron compiles rich data on the uptake of PD-1 inhibitor drugs; A case study in real-world evidence?](https://cdn.cancerletter.com/media/2017/06/data-web.png)
![Flatiron compiles rich data on the uptake of PD-1 inhibitor drugs; A case study in real-world evidence?](https://cdn.cancerletter.com/media/2017/06/data-web.png)
Cover Story
Utilization data compiled by Flatiron Health and made available to The Cancer Letter make it possible to visualize the dramatic uptake of immunotherapy drugs in the academic and community settings.
In Brief
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.